FIELD: pharmaceutical; medicine.
SUBSTANCE: objects 1–3 are methods of treating multiple myeloma in a subject, comprising administering to the subject a therapeutically effective amount of a T-cell expressing a BCMA-specific chimeric antigen receptor (CAR) and a therapeutically effective amount of γ-secretases inhibitor. Object 4 is the use of a T-cell expressing a BCMA-specific chimeric antigen receptor (CAR), with a γ-secretases inhibitor for the treatment of multiple myeloma in a subject. Object 5 is a kit for the treatment of multiple myeloma including T-cells expressing the BCMA-specific chimeric antigen receptor (CAR), and a γ-secretases inhibitor.
EFFECT: effectiveness of the treatment of multiple myeloma by combining T-cells expressing BCMA-specific CAR with a γ-secretases inhibitor.
68 cl, 8 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS TARGETED B-CELL MATURATION ANTIGEN | 2013 |
|
RU2766608C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
| BCMA HEAVY CHAIN ANTIBODIES | 2018 |
|
RU2816994C2 |
| MOLECULES THAT BIND BCMA AND USE OF SUCH MOLECULES | 2019 |
|
RU2812322C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-NK-CELLS | 2020 |
|
RU2795443C2 |
| ANTI-BCMA ANTIBODIES CONTAINING ONLY HEAVY CHAIN | 2017 |
|
RU2781301C2 |
| CD3 BINDING ANTIBODIES | 2017 |
|
RU2807216C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY AGAINST CD20 | 2017 |
|
RU2782699C2 |
